Peptides AcademyMulti-Receptor Metabolic Peptides
Dual GIP/GLP-1 and triple GIP/GLP-1/glucagon agonists — Tirzepatide, Retatrutide — the next-generation of metabolic peptides.
Dual & Triple Agonists (Tirzepatide Class) (2)
Retatrutide
Eli Lilly (investigational)
An investigational triple GIP / GLP-1 / glucagon receptor agonist from Eli Lilly, showing the largest weight-loss effect sizes yet reported in obesity trials (up to ~24% at 48 weeks in phase-2).
Phase 3 investigational (no approvals as of 2026)
Tirzepatide
Mounjaro / Zepbound
First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.
2.5–15 mg weekly (escalating)FDA-approved (Mounjaro T2D, Zepbound obesity)